{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:53:12Z","timestamp":1776707592721,"version":"3.51.2"},"reference-count":22,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/doi.org\/10.37349\/Open_Exploration_Crossmark_Policy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizing hormone-releasing hormone analogs. In patients receiving these drugs, a progressive recession of frontal-temporal hairlines is often observed, such as a certain grade of hair miniaturization in the same areas and the central scalp area, producing a pseudo-female androgenic alopecia, which has to be considered oncotherapy-induced alopecia. The aim of this work, is to describe the clinical aspects and pathogenesis of this type of alopecia and to analyze the different drugs which have been proposed until now. The authors concude that topical hormones should not be considered as a therapeutic approach because of their direct or indirect oncogenic potential. A therapeutic approach that could be both safe and effective is proposed.<\/jats:p>","DOI":"10.37349\/etat.2021.00059","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T04:00:56Z","timestamp":1635739256000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer"],"prefix":"10.37349","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-3423","authenticated-orcid":false,"given":"Alfredo","family":"Rossi","sequence":"first","affiliation":[{"name":"Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-3389","authenticated-orcid":false,"given":"Gemma","family":"Caro","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-7291","authenticated-orcid":false,"given":"Francesca","family":"Magri","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-174X","authenticated-orcid":false,"given":"Maria Caterina","family":"Fortuna","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-2475","authenticated-orcid":false,"given":"Marta","family":"Carlesimo","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21850","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME. Alopecia with endocrine therapies in patients with cancer. Oncologist. 2013;18:1126-34.","DOI":"10.1634\/theoncologist.2013-0193"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619-29.","DOI":"10.1200\/jco.2005.09.121"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.","DOI":"10.1016\/s0140-6736(05)66544-0"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Yi M, Hwang E. Pain and menopause symptoms of breast cancer patients with adjuvant hormonal therapy in Korea: secondary analysis. Asia Pac J Oncol Nurs. 2018;5:262-9.","DOI":"10.4103\/apjon.apjon_45_17"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Hernando C, Ortega-Morillo B, Tapia M, Morag\u00f3n S, Mart\u00ednez MT, Eroles P, et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int J Mol Sci. 2021;22:7812.","DOI":"10.3390\/ijms22157812"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Gateley CA, Bundred NJ. Alopecia and breast disease. BMJ. 1997;314:481.","DOI":"10.1136\/bmj.314.7079.481"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Nonomura Y, Otsuka A, Inui S, Miyachi Y, Kabashima K. Female pattern hair loss possibly caused by tamoxifen: androgen receptor expression in the outer root sheath in the affected area. J Dermatol. 2012;39:1060-1.","DOI":"10.1111\/j.1346-8138.2012.01632.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Ayoub JP, Valero V, Hortobagyi GN. Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med. 1997;126:745-6.","DOI":"10.7326\/0003-4819-126-9-199705010-00033"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Puglisi F, Aprile G, Sobrero A. Tamoxifen-induced total alopecia. Ann Intern Med. 2001;134:1154-5.","DOI":"10.7326\/0003-4819-134-12-200106190-00029"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Park J, Kim JI, Yun SK, Kim HU, Ihm CW. Pattern alopecia during hormonal anticancer therapy in patients with breast cancer. Ann Dermatol. 2014;26:743-6.","DOI":"10.5021\/ad.2014.26.6.743"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, et al. Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol. 2018;154:670-5.","DOI":"10.1001\/jamadermatol.2018.0454"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Ohnemus U, Uenalan M, Inzunza J, Gustafsson JA, Paus R. The hair follicle as an estrogen target and source. Endocr Rev. 2006;27:677-706.","DOI":"10.1210\/er.2006-0020"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Yip L, Zaloumis S, Irwin D, Severi G, Hopper J, Giles G, et al. Gene-wide association study between the aromatase gene (CYP19A1) and female pattern hair loss. Br J Dermatol. 2009;161:289-94.","DOI":"10.1111\/j.1365-2133.2009.09186.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Price VH. Androgenetic alopecia in women. J Investig Dermatol Symp Proc. 2003;8:24-7.","DOI":"10.1046\/j.1523-1747.2003.12168.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Rossi A, Iorio A, Scali E, Fortuna MC, Mari E, Maxia C, et al. Aromatase inhibitors induce \u2018male pattern hair loss\u2019 in women? Ann Oncol. 2013;24:1710-1.","DOI":"10.1093\/annonc\/mdt170"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Hoffmann R, Niiyama S, Huth A, Kissling S, Happle R. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol. 2002;11:376-80.","DOI":"10.1034\/j.1600-0625.2002.110413.x"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Bhargava S. Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer. Med Hypotheses. 2014;82:428-32.","DOI":"10.1016\/j.mehy.2014.01.016"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Rossi A, Anzalone A, Fortuna MC, Caro G, Garelli V, Pranteda G, et al. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016;29:424-32.","DOI":"10.1111\/dth.12390"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Glaser DA, Hossain P, Perkins W, Griffiths T, Ahluwalia G, Weng E, et al. Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol. 2015;172:1384-94.","DOI":"10.1111\/bjd.13443"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Rossi A, Caro G, Fortuna MC, Pigliacelli F, D\u2019Arino A, Carlesimo M. Prevention and treatment of chemotherapy-induced alopecia. Dermatol Pract Concept. 2020;10:e2020074.","DOI":"10.5826\/dpc.1003a74"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Caro G, Fortuna MC, Magri F, Federico A, Carlesimo M, Rossi A. A new treatment of alopecia induced by palbociclib: topical cetirizine. J Oncol Pharm Pract. 2021;27:460-3.","DOI":"10.1177\/1078155220930334"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, et al. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat. 2018;29:149-51.","DOI":"10.1080\/09546634.2017.1341610"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"link":[{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/100259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T04:01:01Z","timestamp":1635739261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/100259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":22,"URL":"https:\/\/doi.org\/10.37349\/etat.2021.00059","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"assertion":[{"value":"2021-6-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-31","order":2,"name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}